Molecular Partners AG
SIX:MOLN

Watchlist Manager
Molecular Partners AG Logo
Molecular Partners AG
SIX:MOLN
Watchlist
Price: 4.63 CHF 8.69% Market Closed
Market Cap: 186.9m CHF
Have any thoughts about
Molecular Partners AG?
Write Note

Molecular Partners AG
Total Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Molecular Partners AG
Total Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Molecular Partners AG
SIX:MOLN
Total Current Liabilities
CHf11.4m
CAGR 3-Years
-42%
CAGR 5-Years
-20%
CAGR 10-Years
N/A
ADC Therapeutics SA
NYSE:ADCT
Total Current Liabilities
$67.7m
CAGR 3-Years
19%
CAGR 5-Years
25%
CAGR 10-Years
N/A
AC Immune SA
NASDAQ:ACIU
Total Current Liabilities
CHf101m
CAGR 3-Years
92%
CAGR 5-Years
48%
CAGR 10-Years
N/A
CRISPR Therapeutics AG
NASDAQ:CRSP
Total Current Liabilities
$89.8m
CAGR 3-Years
-2%
CAGR 5-Years
2%
CAGR 10-Years
N/A
Basilea Pharmaceutica AG
SIX:BSLN
Total Current Liabilities
CHf37.8m
CAGR 3-Years
0%
CAGR 5-Years
-14%
CAGR 10-Years
-3%
Kuros Biosciences AG
SIX:KURN
Total Current Liabilities
CHf12.2m
CAGR 3-Years
48%
CAGR 5-Years
31%
CAGR 10-Years
N/A
No Stocks Found

Molecular Partners AG
Glance View

Market Cap
186.9m CHF
Industry
Biotechnology

Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. The company is headquartered in Schlieren, Zuerich and currently employs 163 full-time employees. The company went IPO on 2014-10-22. The firm has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.

MOLN Intrinsic Value
2.91 CHF
Overvaluation 37%
Intrinsic Value
Price

See Also

What is Molecular Partners AG's Total Current Liabilities?
Total Current Liabilities
11.4m CHF

Based on the financial report for Jun 30, 2024, Molecular Partners AG's Total Current Liabilities amounts to 11.4m CHF.

What is Molecular Partners AG's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
-20%

Over the last year, the Total Current Liabilities growth was -28%. The average annual Total Current Liabilities growth rates for Molecular Partners AG have been -42% over the past three years , -20% over the past five years .

Back to Top